Probabilistic risk analysis: Improving early drug development decision making

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 6, 2010, Pages 871-875

  Mudd Jr , P N ^a   Groenendaal, H ^b   Bush, M A ^a   Schmith, V D ^a  

^a GLAXOSMITHKLINE   (United States)

^b Vose Consulting US LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACOLOGY; DRUG DEVELOPMENT; DRUG EFFICACY; EXPERIMENTAL MODEL; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; METHODOLOGY; MODEL BASED DRUG DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROBABILISTIC RISK ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; UNCERTAINTY;

ANIMALS; DECISION MAKING, ORGANIZATIONAL; DRUG DISCOVERY; HUMANS; MODELS, STATISTICAL; RISK ASSESSMENT;

EID: 78549247082     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.231     Document Type: Review

References (29)

1. Pisano, G.P. can science be a business? Lessons from biotech. Harv. Bus. Rev. 84, 114-24, 150 (2006).
2. diMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272-277 (2010).
3. Vose, d. Risk Analysis: a Quantitative Guide, 3rd edn. 3-65, 585-713 (Wiley, chichester, West Sussex, UK, 2008).
4. Cox, L.A. Risk Analysis of Complex and Uncertain Systems. 3-72 (Springer, New York, 2009).
5. Clemen, R.T. Making Hard Decisions. 1-12, 249-280, 496-517 (South-Western, Florence, KY, 2004).
6. Hubbard, d.W. The Failure of Risk Management. Why It's Broken and How to Fix It. 26-27, 61, 95-115, 203-207, 254-259 (Wiley, Hoboken, NJ, 2009).
7. Sheiner, L.B. Learning versus confrming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997).
8. US Food and drug Administration. challenge and Opportunity on the critical Path to New Medical Products. critical Path Initiative (2004).
9. Stanski, d.R. Model-Based drug development: A critical Path Opportunity. critical Path Initiative (2004).
10. Zhang, L. et al. Model-based drug development: the road to quantitative pharmacology. J. Pharmacokinet. Pharmacodyn. 33, 369-393 (2006).
11. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
12. Peck, C.C. et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J. Clin. Pharmacol. 34, 111-119 (1994).
13. Holford, N.H., Kimko, H.c., Monteleone, J.P. & Peck, c.c. Simulation of clinical trials. Annu. Rev. Pharmacol. Toxicol. 40, 209-234 (2000).
14. Galluppi, G.R. et al. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin. Pharmacol. Ther. 69, 387-399 (2001).
15. Chien, J.Y., Friedrich, S., Heathman, M.A., de Alwis, d.P. & Sinha, V. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J. 7, E544-E559 (2005).
16. Honig, P. & Lalonde, R. The economics of drug development: a grim reality and a role for clinical pharmacology. Clin. Pharmacol. Ther. 87, 247-251 (2010).
17. Gobburu, J.V. & Sekar, V.J. Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. Int. J. Clin. Pharmacol. Ther. 40, 281-288 (2002).
18. Patterson, S.D. Experiences with learning and confrming in drug and biological development. Clin. Pharmacol. Ther. 88, 161-163 (2010).
19. Hubbard, D.W. How to Measure Anything. 85-99 (Wiley, Hoboken, NJ, 2007).
20. Willan, A.R. Optimal sample size determinations from an industry perspective based on the expected value of information. Clin. Trials 5, 587-594 (2008).
21. Willan, A.R. & Eckermann, S. Optimal clinical trial design using value of information methods with imperfect implementation. Health Econ. 19, 549-561 (2010).
22. diMasi, J.A. & Grabowski, H.G. The cost of biopharmaceutical R&d: is biotech diferent? Managerial Dec. Econ. 28, 469-479 (2007).
23. Kynn, M. The 'heuristics and biases' bias in expert elicitation. J.R. Statist. Soc. A. 171(Pt 1), pp. 239-264 (2008).
24. Tversky, A. & Kahneman, d. Judgment under uncertainty: heuristics and biases. Science 185, 1124-1131 (1974).
25. Johnson, B., Groenendaal H., & Mudd, P.N. Jr. Novel application of Bayesian model averaging for more robust PK/Pd simulations and improved decision making [abstr]. Annual Meeting of the American Society for clinical Pharmacology and Therapeutics, Atlanta, GA, 17-20 March 2010.
26. Poland, B. et al. The clinical utility index as a practical multiattribute approach to drug development decisions. Clin. Pharmacol. Ther. 86, 105-108 (2009).
27. Mussen, F., Salek, S. & Walker, S. A quantitative approach to benefit-risk assessment of medicines-part 1: the development of a new model using multi-criteria decision analysis. Pharmacoepidemiol. Drug Saf. 16 (suppl. 1), S2-S15 (2007).
28. Hughes, D.A., Bayoumi, A.M. & Pirmohamed, M. current assessment of risk-benefit by regulators: is it time to introduce decision analyses? Clin. Pharmacol. Ther. 82, 123-127 (2007).
29. Ouellet, D., Werth, J., Parekh, N., Feltner, D., Mccarthy, B. & Lalonde, R.L. The use of a clinical utility index to compare insomnia compounds: a quantitative basis for benefit-risk assessment. Clin. Pharmacol. Ther. 85, 277-282 (2009).